Portal de Periódicos da CAPES

Shortened progression free and overall survival to immune-checkpoint inhibitors in BRAF-, RAS- and NF1- (“Triple”) wild type melanomas

2024; Elsevier BV; Volume: 208; Linguagem: Inglês

10.1016/j.ejca.2024.114208

1879-0852

Philipp Jansen, Wolfgang Galetzka, Georg Lodde, Fabian Standl, Anne Zaremba, Rudolf Herbst, Patrick Terheyden, Jochen Utikal, Claudia Pföhler, Jens Ulrich, Alexander Kreuter, Peter Mohr, Ralf Gutzmer, Friedegund Meier, Edgar Dippel, Michael Weichenthal, Jan-Malte Placke, Jennifer Landsberg, Inga Möller, Antje Sucker, Annette Paschen, Eva Hadaschik, Lisa Zimmer, Elisabeth Livingstone, Dirk Schadendorf, Selma Ugurel, Andreas Stang, Klaus Griewank,

Cancer Immunotherapy and Biomarkers

Melanomas lacking mutations in BRAF, NRAS and NF1 are frequently referred to as "triple wild-type" (tWT) melanomas. They constitute 5-10 % of all melanomas and remain poorly characterized regarding clinical characteristics and response to therapy. This study investigates the largest multicenter collection of tWT-melanomas to date.